Type 2 diabetes

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resist

Retrieved on: 
Friday, December 8, 2023

REDWOOD CITY, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase II clinical study (COVALENT-111) and data from preclinical ex-vivo human islet experiments of BMF-219, the company’s investigational oral covalent menin inhibitor.

Key Points: 
  • “Our goal with BMF-219 is to create a short-term treatment regimen for patients with diabetes that results in long term glycemic control.
  • These early clinical results of improved glycemic control over time while patients are off treatment have been very impressive.
  • Phase II consists of multiple ascending dose (MAD) cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

Clinical Research Shows the Active Ingredient in Mikra’s Serenity Matches a Benzodiazepine in Effectiveness at Fighting Anxiety, Without Being Habit-Forming

Retrieved on: 
Wednesday, December 6, 2023

TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that European clinical research demonstrated that the active ingredient in Serenity, the newest product from its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”), is equally effective as a prescription-only benzodiazepine in treating the symptoms of anxiety.

Key Points: 
  • This research was particularly noteworthy because benzodiazepines, while widely prescribed for anxiety, carry substantial risk of dependency and of seizures in case of withdrawal2.
  • “It was this understanding that drove us to accelerate the launch of Serenity.
  • With Lifeist's expertise with fragrant and flavorful botanicals, Serenity is poised to become the best tasting lavender oil extract supplement on the market.
  • Plus, Serenity ships with a full 30-day supply in every bottle, as compared to the typical 7- or 14-day supply sold in competing lavender-based products.

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

Retrieved on: 
Tuesday, December 5, 2023

REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Health Canada has cleared Biomea's Clinical Trial Application (CTA) to study BMF-219 in adults living with type 1 diabetes.

Key Points: 
  • Beta cell loss is a root cause of type 1 and type 2 diabetes.
  • Preclinical studies have shown the potential of BMF-219 to specifically regenerate and retain insulin-producing beta cells in animal models of type 1 and type 2 diabetes.
  • The trial will also include an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • “Our study COVALENT-111 is currently enrolling persons with type 2 diabetes and has generated tremendous enthusiasm among investigators in Canada.

LiveCare Continues Rapid Growth and Expansion into Key States

Retrieved on: 
Tuesday, December 5, 2023

Venice, FL, USA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- LiveCare, Inc. (OTC: LVCE), a leader in the telehealth industry, announces expansion into key states and ambitious expansion into national markets.

Key Points: 
  • Venice, FL, USA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- LiveCare, Inc. (OTC: LVCE), a leader in the telehealth industry, announces expansion into key states and ambitious expansion into national markets.
  • Initially licensed and credentialed only in Florida, LiveCare has now expanded to Texas, Ohio, and Michigan, tapping into a potential customer base of 27.4 million.
  • Max Rockwell, CEO of LiveCare, stated, "This significant growth in our daily member acquisitions and our expansion into key states is a testament to our commitment to providing accessible, high-quality healthcare solutions.
  • Stay tuned for more updates as LiveCare continues to broaden its services and impact in the healthcare industry.

New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure

Retrieved on: 
Tuesday, November 28, 2023

Obesity and high blood pressure are significant risk factors for the development of cardiovascular disease.

Key Points: 
  • Obesity and high blood pressure are significant risk factors for the development of cardiovascular disease.
  • “QSYMIA offers a differentiated profile consisting of demonstrated efficacy with respect to weight loss and blood pressure reduction, well-defined safety, convenient once-daily oral administration, and cost-effectiveness.
  • The once-daily pill is currently covered by the majority (81%) of commercial healthcare plans and is indicated for long-term use.
  • Importantly, obesity increases the risk of type 2 diabetes, hypertension and dyslipidemia, thereby increasing the risk of cardiovascular disease and mortality.

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

Retrieved on: 
Monday, November 27, 2023

These abstracts further validate the mechanism of action of covalently inhibiting menin in people with type 2 diabetes to potentially provide long-term improvement in glycemic control through beta cell regeneration.

Key Points: 
  • These abstracts further validate the mechanism of action of covalently inhibiting menin in people with type 2 diabetes to potentially provide long-term improvement in glycemic control through beta cell regeneration.
  • Biomea will disclose additional information about the presentations in accordance with the ATTD abstract embargo policies.
  • Phase II consists of multiple ascending dose cohorts and dose durations and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

Retrieved on: 
Monday, November 27, 2023

In this study, Truveta Research explored weight loss trends for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively).

Key Points: 
  • In this study, Truveta Research explored weight loss trends for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively).
  • The study found that in the initial unadjusted population, those taking tirzepatide and semaglutide differed.
  • The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss:
    Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss,
    2.6 times more likely than those taking semaglutide to achieve 10% weight loss,
    And three times more likely than those taking semaglutide to achieve 15% weight loss.
  • At six months, the mean percentage change in body weight was -10.1% for those taking tirzepatide versus -5.9% for those taking semaglutide.

Inventiva reports 2023 Third Quarter Financial Information¹

Retrieved on: 
Tuesday, November 21, 2023

Net cash used in operating activities amounted to (€69.0) million in the first nine months of 2023, compared to (€40.1) million for the same period in 2022.

Key Points: 
  • Net cash used in operating activities amounted to (€69.0) million in the first nine months of 2023, compared to (€40.1) million for the same period in 2022.
  • R&D expenses for the first nine months of 2023 were up 86 % compared to the same period in 2022.
  • The Company’s revenues for the first nine months of 2023 amounted to €1.9 million, stable from the first six months of 2023, compared to €0.1 million for the same period in 2022.
  • Inventiva has exercised the option to acquire 30% of the shares Hepalys Pharma for the price of 300 yen.

Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity

Retrieved on: 
Thursday, November 16, 2023

The new research, to be led by Professor Randy Seeley, Ph.D., of Michigan Medicine, is intended to explore the mechanistic rationale underlying the use of local pancreatic gene therapy to produce targeted treatment options that address, and hopefully remit, metabolic diseases.

Key Points: 
  • The new research, to be led by Professor Randy Seeley, Ph.D., of Michigan Medicine, is intended to explore the mechanistic rationale underlying the use of local pancreatic gene therapy to produce targeted treatment options that address, and hopefully remit, metabolic diseases.
  • “T2D and obesity are two of society’s most vexing chronic diseases.
  • We now have much better tools in the toolbox, but all rely on chronic therapy to achieve their benefits.
  • “We are excited to deepen our scientific collaboration with Dr. Seeley to explore the metabolic mechanisms underpinning a one-time gene therapy in the pancreas.”

ACADEMY OF NUTRITION AND DIETETICS: NUTRITION PLAYS VITAL ROLE IN MANAGING DIABETES

Retrieved on: 
Thursday, November 16, 2023

In addition, 96 million adults have prediabetes, with more than 80% unaware they have it.

Key Points: 
  • In addition, 96 million adults have prediabetes, with more than 80% unaware they have it.
  • Registered dietitian nutritionists, who are the food and nutrition experts, are uniquely educated and trained to provide medical nutrition therapy, which includes regular therapeutic and counseling services to help patients manage prediabetes and diabetes, Tewksbury says.
  • Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.
  • The Academy is committed to improving health and advancing the profession of dietetics through research, education and advocacy.